Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aalborg Hospital, Aalborg, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients older than 18-year-old, diagnosed with cancer
Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

Exclusion criteria

Patients who cannot complete a PET/CT scan
Pregnant women
Healthy volunteers
Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.

Treatment and study plan

Primary outcomes

Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT.

Time frame: not defined

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start: 2007
Primary completion: 2018
Study completion: 2019
First posted: Jul 30, 2008
Registry last updated: Sep 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed